AIFF Firefly Neuroscience Inc.

$AIFF Firefly Neuroscience (NASDAQ: AIFF) Strengthens Non-Invasive Brain-Computer Interface Growth Strategy with Commercially Available Versus Platform

$AIFF Retracting my earlier post The misunderstanding came from mixing three different levels of evidence: 1. A third-party aggregator, SeedOps, reported a statement attributed to Cognito: “Next month at CTAD, we’ll share the results of our pivotal HOPE study.” That appeared in an October 13 activity record and was published later. 2. I treated that aggregator entry as if it were a directly verified Cognito press release or official CTAD program entry. That was my mistake. 3. When I checked Cognito’s website and the CTAD listing, I found only an OVERTURE biomarker poster clearly listed. I then swung too far in the other direction and said the CTAD HOPE announcement was unconfirmed, without adequately acknowledging that the SeedOps entry may have captured a genuine Cognito social-media post.

$AIFF HOPE presentation remains scheduled for: Monday, November 16, 2026 5:45 p.m. Eastern / 2:45 p.m. Pacific CTAD 2026, Boston The official program lists it as LB01, titled: “Spectris Treatment in Mild-to-Moderate Alzheimer’s Disease: Topline Results and Secondary Analyses From the HOPE Pivotal Study.” Presenters remain Roy Hamilton, Ralph Kern, Robbert Zusterzeel, and Marwan Sabbagh. CTAD’s current press information also confirms that sessions will be livestreamed, but access requires conference registration. Recordings are expected to be available to registered attendees within 48 hours.

$AIFF Finally! Just Announced Cognito says it will share results from its pivotal 673-patient HOPE study at CTAD, Nov. 16–19 in Boston. After a long wait, we finally have a defined timeline. For $AIFF, I’ll be watching for any Firefly EEG findings—and whether brain-state changes align with clinical outcomes and MRI. Big potential catalyst; results are still unknown. #Alzheimers